Literature DB >> 21871474

Inducible bilirubin oxidase: a novel function for the mouse cytochrome P450 2A5.

A'edah Abu-Bakar1, Dionne Maioha Arthur, Simona Aganovic, Jack C Ng, Matti A Lang.   

Abstract

We have previously shown that bilirubin (BR), a breakdown product of haem, is a strong inhibitor and a high affinity substrate of the mouse cytochrome P450 2A5 (CYP2A5). The antioxidant BR, which is cytotoxic at high concentrations, is potentially useful in cellular protection against oxygen radicals if its intracellular levels can be strictly controlled. The mechanisms that regulate cellular BR levels are still obscure. In this paper we provide preliminary evidence for a novel function of CYP2A5 as hepatic "BR oxidase". A high-performance liquid chromatography/electrospray ionisation mass spectrometry screening showed that recombinant yeast microsomes expressing the CYP2A5 oxidise BR to biliverdin, as the main metabolite, and to three other smaller products with m/z values of 301, 315 and 333. The metabolic profile is significantly different from that of chemical oxidation of BR. In chemical oxidation the smaller products were the main metabolites. This suggests that the enzymatic reaction is selective, towards biliverdin production. Bilirubin treatment of primary hepatocytes increased the CYP2A5 protein and activity levels with no effect on the corresponding mRNA. Co-treatment with cycloheximide (CHX), a protein synthesis inhibitor, resulted in increased half-life of the CYP2A5 compared to cells treated only with CHX. Collectively, the observations suggest that the CYP2A5 is potentially an inducible "BR oxidase" where BR may accelerate its own metabolism through stabilization of the CYP2A5 protein. It is possible that this metabolic pathway is potentially part of the machinery controlling intracellular BR levels in transient oxidative stress situations, in which high amounts of BR are produced. Crown
Copyright © 2011. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21871474     DOI: 10.1016/j.taap.2011.08.011

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  8 in total

Review 1.  Alcoholic Liver Disease: from CYP2E1 to CYP2A5.

Authors:  Tung Ming Leung; Yongke Lu
Journal:  Curr Mol Pharmacol       Date:  2017       Impact factor: 3.339

2.  Ethanol induction of CYP2A5: role of CYP2E1-ROS-Nrf2 pathway.

Authors:  Yongke Lu; Xu Hannah Zhang; Arthur I Cederbaum
Journal:  Toxicol Sci       Date:  2012-05-02       Impact factor: 4.849

3.  Alcohol Upregulation of CYP2A5: Role of Reactive Oxygen Species.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  React Oxyg Species (Apex)       Date:  2016-03

Review 4.  Cytochrome P450s and Alcoholic Liver Disease.

Authors:  Yongke Lu; Arthur I Cederbaum
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

5.  Modulation of cytochrome P450 2A5 activity by lipopolysaccharide: low-dose effects and non-monotonic dose-response relationship.

Authors:  Ana C A X De-Oliveira; Kátia S Poça; Paulo R R Totino; Francisco J R Paumgartten
Journal:  PLoS One       Date:  2015-01-30       Impact factor: 3.240

6.  Heme Degradation by Heme Oxygenase Protects Mitochondria but Induces ER Stress via Formed Bilirubin.

Authors:  Andrea Müllebner; Rudolf Moldzio; Heinz Redl; Andrey V Kozlov; J Catharina Duvigneau
Journal:  Biomolecules       Date:  2015-04-30

7.  Identification of a biliverdin geometric isomer by means of HPLC/ESI-MS and NMR spectroscopy. Differentiation of the isomers by using fragmentation "in-source".

Authors:  Rafał Frański; Błażej Gierczyk; Łukasz Popenda; Małgorzata Kasperkowiak; Tomasz Pędzinski
Journal:  Monatsh Chem       Date:  2018-02-13       Impact factor: 1.451

8.  Cytochrome P450 1A2 Is Incapable of Oxidizing Bilirubin Under Physiological Conditions.

Authors:  Xinyi Li; Dongzhen Yu; Huiqun Jie; Huiqun Zhou; Haibo Ye; Guo Ma; Lili Wan; Chunyan Li; Haibo Shi; Shankai Yin
Journal:  Front Pharmacol       Date:  2019-10-18       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.